CSPC Pharmaceutical Group’s Stock Price Drops to 4.82 HKD, Plunging by 4.18% in Latest Market Update

CSPC Pharmaceutical Group (1093)

4.82 HKD -0.21 (-4.18%) Volume: 227.48M

CSPC Pharmaceutical Group’s stock price is currently at 4.82 HKD, experiencing a decline of -4.18% in this trading session with a trading volume of 227.48M, yet showcasing a modest YTD increase of +0.84%. Stay updated with the latest performance of 1093 stock price.

Latest developments on CSPC Pharmaceutical Group

CSPC Pharmaceutical Group shocked investors today with a profit warning following a significant decline in revenue. The company’s stock price took a hit after announcing an expected 25 percent drop in net profit. This news came on the heels of Radiance’s acquisition of ROR1 ADC rights from CSPC in a deal valued at over $1 billion. These key events have contributed to the volatile movement in CSPC Pharmaceutical Group‘s stock price today.

A look at CSPC Pharmaceutical Group Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Based on the Smartkarma Smart Scores, CSPC Pharmaceutical Group shows a promising long-term outlook. With high scores in Dividend and Value, investors can expect steady returns and a company that is potentially undervalued in the market. Additionally, strong scores in Growth and Resilience indicate that CSPC Pharmaceutical Group is well-positioned for future expansion and able to withstand economic challenges. However, the lower score in Momentum suggests that the company may be facing some short-term obstacles or slower market traction.

CSPC Pharmaceutical Group Limited is a pharmaceutical company that focuses on manufacturing and selling a variety of pharmaceutical products, including vitamin C, antibiotics, and generic drugs. The company also has a focus on developing innovative drugs and antibiotics. With high scores in Dividend, Value, Growth, and Resilience according to Smartkarma Smart Scores, CSPC Pharmaceutical Group appears to be a solid investment option for those looking for a stable company with growth potential in the pharmaceutical industry.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma